title: [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
abstract: Because mFOLFOX6 has few contraindications, it is useful for poor performance status(PS)cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6(first-line)for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.
authors.affiliation: Kawasaki Comprehensive Care Center, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Nishi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hamamoto
authors.forename: Junko
authors.initials: J
authors.lastname: Uemoto
authors.forename: Kei
authors.initials: K
authors.lastname: Onodera
authors.forename: Etsuko
authors.initials: E
authors.lastname: Warita
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yamanaka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000627:therapeutic use
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil